{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huynh U"],"funding":["National Institute of General Medical Sciences","NIGMS NIH HHS"],"pagination":["849-857"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9928872"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(2)"],"pubmed_abstract":["Targeted drug delivery using antibody-drug conjugates has attracted great attention due to its enhanced therapeutic efficacy compared to traditional chemotherapy. However, the development has been limited due to a low drug-to-antibody ratio and laborious linker-payload optimization. Herein, we present a simple and efficient strategy to combine the favorable features of polymeric nanocarriers with antibodies to generate an antibody-nanogel conjugate (ANC) platform for targeted delivery of cytotoxic agents. Our nanogels stably encapsulate several chemotherapeutic agents with a wide range of mechanisms of action and solubility. We showcase the targetability of ANCs and their selective killing of cancer cells over-expressing disease-relevant antigens such as human epidermal growth factor receptor 2, epidermal growth factor receptor, and tumor-specific mucin 1, which cover a broad range of breast cancer cell types while maintaining low to no toxicity to non-targeted cells. Overall, our system represents a versatile approach that could impact next-generation nanomedicine in antibody-targeted therapeutics."],"journal":["Biomacromolecules"],"pubmed_title":["Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate."],"pmcid":["PMC9928872"],"funding_grant_id":["GM-136395","T32 GM135096","R35 GM136395"],"pubmed_authors":["Qiu J","Singh K","Wu P","Gao J","Thayumanavan S","Prachyathipsakul T","Jerry DJ","Huynh U"],"additional_accession":[]},"is_claimable":false,"name":"Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate.","description":"Targeted drug delivery using antibody-drug conjugates has attracted great attention due to its enhanced therapeutic efficacy compared to traditional chemotherapy. However, the development has been limited due to a low drug-to-antibody ratio and laborious linker-payload optimization. Herein, we present a simple and efficient strategy to combine the favorable features of polymeric nanocarriers with antibodies to generate an antibody-nanogel conjugate (ANC) platform for targeted delivery of cytotoxic agents. Our nanogels stably encapsulate several chemotherapeutic agents with a wide range of mechanisms of action and solubility. We showcase the targetability of ANCs and their selective killing of cancer cells over-expressing disease-relevant antigens such as human epidermal growth factor receptor 2, epidermal growth factor receptor, and tumor-specific mucin 1, which cover a broad range of breast cancer cell types while maintaining low to no toxicity to non-targeted cells. Overall, our system represents a versatile approach that could impact next-generation nanomedicine in antibody-targeted therapeutics.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-03T23:51:04.866Z","creation":"2025-04-03T23:51:04.866Z"},"accession":"S-EPMC9928872","cross_references":{"pubmed":["36639133"],"doi":["10.1021/acs.biomac.2c01269"]}}